zinc finger and SCAN domain containing 29Genealiases: ZNF690 · Zfp690
Q-omics provides the consensus-scored ZSCAN29 profile across patient tissues and cancer cell-line models. ZSCAN29 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN29 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZSCAN29 RNA expression shows 21,176 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ZSCAN29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN29 survival associations across molecular data types. ZSCAN29 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN29 RNA expression–survival associations across cancer types. High ZSCAN29 expression shows unfavorable associations in KIRP, OV, ACC and KICH, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZSCAN29 RNA expression.
This table summarizes ZSCAN29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN29 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, STAD and CHOL. The HNSC box plot shows higher ZSCAN29 RNA expression in tumor versus normal tissue (log2 FC = +1.281, t-test p < 0.001).
This table shows molecular features associated with ZSCAN29 in patient tissues and cancer cell lines. In patient samples, ZSCAN29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
